Try our Advanced Search for more refined results
Life Sciences - April, 2024
300 articles
- Ex-Olympus Exec Says He Was Fired For Flagging FDA Issue
- Judge Strikes Parts Of NC Law Restricting Abortion Drug
- Tech. Orgs Deny Being 'Apple's Puppets' In Watch Ban Fight
- Chase Can't Escape Medical Services Co.'s Defamation Suit
- Pharmacyclics Can't Score Fees After Imbruvica Patent Win
- Amgen Cuts Deal To End Bone Drug IP Suit Against Sandoz
- SEC Fines 3 Men For Insider Trading On Zogenix Buyout
- BCBS Says Federal Drug Law Preempts NM Medical Weed Row
- Pfizer Can't Slip COVID-19 Vax Suit, Texas Tells Court
- Drug Company Can't Escape Texas Counties' Opioid MDL
- 3rd Circ. Preview: Kavanaugh Classmate Takes On HuffPost
- Judge Tosses LTL's Suit Over Article Linking Talc To Cancer
- FTC Continues To Target 'Junk' Drug Patents
- Vaxart Investors Want Sanctions Over Deleted Texts
- Feds Endorse Easing Marijuana Status In Big Policy Shift
- Don't Miss It: McDermott, Paul Weiss Lead Month's Hot Deals
- Think Like A Lawyer: Follow The Iron Rule Of Trial Logic
- Medical Device Biz Hologic To Buy UK Rival For $310M
- Pfizer Inks $25M Deal Ending Leftover Effexor Antitrust Claims
- Judge Rejects 2 Challenges To Medicare Drug Price Talks
- Sandoz Says Biopharma Biz Added 'Poison' To Market
- Mistrial Called In $86M Stent Patent Case Against Medtronic
- Boehringer Accused Of Monopolizing Inhaler Product Market
- Pharma Co. Hit With Investor Suit Over Liver Drug Trials
- HHS Delays Menthol Cigarette Ban Indefinitely
- Amid Backlash, FDA Extends Control For Lab-Developed Tests
- Catching Up With Delaware's Chancery Court
- AI Pharma Co. Sued By Investor Over Handling Of Fired CEO
- Alcon Owes $34M In Glaucoma Patent Row, Jury Finds
- 4th Circ. OKs Sanctions Against Law Firm In Bestwall Ch. 11
- PTAB Rejects Masimo's Concurrent Bid To Review Apple Patent
- Judge Rejects Class Certification Of Seizure Drug Customers
- The Art Of Asking: Leveraging Your Contacts For Referrals
- Connecticut Firm Seeks $500K Fee In Magnesium Class Action
- Deciphera Stock Soars On $2.4B Deal With Japan's Ono
- Justices To Weigh RICO Injury Scope In CBD Case
- Philips Inks $1.1B Deal To Resolve CPAP Injury Claims
- Law360 Reveals Titans Of The Plaintiffs Bar
- Ex-McKinsey Partner Says Firm Made Him Opioids 'Scapegoat'
- New FDA Official Talks Food Safety After Formula Outbreak
- Ex-USPTO Solicitor Heads To Carmichael IP
- Trending At The PTAB: Permissible New Reply Arguments
- Latham, Akin Beat NJ Suit Over Alleged IP Theft Scheme
- Ga. Residents Want In On $300M Monkey Farm Fight
- Wave Of Final Rules Reflects Race Against CRA Deadline
- 'Beauty From Within' Trend Poses Regulatory Risks For Cos.
- QuidelOrtho Execs Lied About COVID Test Revenue, Suit Says
- Astellas Can't Block Generic Myrbetriq Amid Patent Suit
- CureVac, Acuitas Reach Deal In COVID Vax Patent Dispute
- GSK Hits Pfizer And BioNTech With COVID Vaccine Patent Suit
- Stryker Says Sanctions Bid Goes 'Galaxies Beyond' Law
- 3rd Circ. Lets Mallinckrodt Off Sanofi's Royalty Hook
- Becton BIPA Suit Gets Cut Short Under Health Exception
- Philips Gets $506M Economic Loss Deal OK'd In CPAP MDL
- McKesson May Change How AKS-Based FCA Claims Are Pled
- NC Hospital Leader Condemns FTC's Merger Block Bid
- Ex-Burns & Levinson Life Sciences Chair Joins Polsinelli
- Conn. Judge In Drug Price-Fixing Suit Reveals Day Pitney Ties
- Class Counsel Seeks $31M From $93M Lipitor Settlement
- Being An Equestrian Makes Me A Better Lawyer
- Wachtell Steers Perrigo In €275M Unit Sale To Pharma Biz
- Motley Rice, Morgan & Morgan Among Ozempic MDL Leaders
- DEA's Upcoming Decision On Cannabis Likely To Be Litigated
- UPMC Affiliate Can't Avoid False Claims Suit Over NIH Grant
- NGM Biopharma Investor Seeks Stock Appraisal In Del.
- FDA Can Keep Most Docs Hidden From Juul's FOIA Request
- Joe Rogan Brain Health Supplements Don't Work, Suit Claims
- 7th Circ. Mootness Fee Case May Curb Frivolous Merger Suits
- Fintiv Denials Are On The Rise At PTAB
- Private Equity Lag Continues To Stunt M&A Growth
- 4 Ways To Refresh Your Law Firm's Marketing Strategy
- Calif. Fertility Clinic Implanted Dead Embryos, Couples Say
- Medtronic Patent Fight With Axonics Set For September Trial
- GoodRx Hid Revenue Reliance On Kroger, Suit Claims
- Israeli Biotech Files Ch. 15 To Implement Take-Private Deal
- Ex-Takeda Worker, Boyfriend To Plead Guilty In Invoice Scam
- Drugmakers Hit With RICO Suit Over Insulin Price Hikes
- Fenwick, Covington Build $750M Sale Of Pharmaceutical Biz
- Pre-Merger Deal Prompts Pharma Co. Derivative Suit In Del.
- Cos. Must Prepare For Calif. Legislation That Would Ban PFAS
- Colo. Neural Privacy Law Has Attys Scratching Their Heads
- HHS Finalizes Rule Bolstering Abortion Privacy Protections
- Eli Lilly Tells Fed. Circ. $177M Patent Loss Was Rightly Axed
- 9th Circ. Backs Class Cert. In Pet Supplement False Ad Suit
- J&J Fired Worker For Old Case Against New Boss, Suit Claims
- J&J Hit With $45M Talc Verdict In Illinois Cancer Trial
- Opioid Marketer Completes $1.5M Damages Settlement With Del.
- FDA Warning Letter Tightens Reins On 'Research Only' Labels
- Broker In Penny Stock Scheme Says SEC Is Forum Shopping
- DEA Tells 9th Circ. 'Right To Try' Doesn't Rewrite CSA
- J&J Says Worker's Drug Costs Suit Misses Big Picture
- Catching Up With Delaware's Chancery Court
- Thermo Fisher Says Rival Is Raiding Its Workforce
- Supreme Court Won't Review Vanda's IP Obviousness Appeal
- Allergan To Face Kickback Claim In Suit Over Child Botox Use
- Judge Mulls Axing Biomedical Cos.' $25M Punitive Damages
- Flint Class Urges Approval Of $25M Water Firm Settlement
- Walgreens Inks $110M Deal To End Philly Opioid Crisis Suit
- J&J Unit Sued Over Defective Knee Replacements
- Blumenauer: This 4/20 Will Be The Last For Schedule I Pot
- Practical Pointers After Fed. Circ. Double-Patenting Decision
- Highlights From The 2024 ABA Antitrust Spring Meeting
- UK Litigation Roundup: Here's What You Missed In London
- USPTO Reveals Scaled-Back Plan For New Patent Board Rules
- NY Fertility Clinic Must Face Lost, Damaged Embryos Suit
- EU Antitrust Chief Says Merger Tool Not A 'Power Grab'
- Pharma Ex-Exec Can't Revive $12M Underpayment Suit in US
- J&J Notches Win In Fla. Talcum Powder Trial
- Pharma Co. Wants Tribe's Opioid Suit To Stay In Federal Court
- Endo Pleads Guilty To Marketing Opioids As 'Crush Proof'
- 23andMe Taps Dechert To Review CEO Buyout Proposal
- FDA Head Gets GOP Rep.'s Rebuke Over Pot Rescheduling
- Biotech Co. NanoString Lands $393M Bid At Ch. 11 Auction
- Strategies For Challenging A Fla. Grand Jury Report's Release
- Trial-Ready Paraquat MDL Cases Tossed After Testimony Axed
- Walgreens Investors' $36M Deal In Opioid Suit Gets First OK
- PTC Therapeutics Settles Shareholder Suit Over Director Pay
- United Therapeutics Can't Bar Rival Lung Disease Drug
- Kraft Sued Over Lead Contamination In Lunchables
- J&J Tells Jurors To Look To Evidence And Science In Talc Trial
- Karuna Investor Ends Suit After Bristol-Myers Seals $14B Deal
- Jury To Decide Fault Of Driver In Spray-Huffing DUI Death
- 3 Takeaways From Revived Obviousness Case On J&J Patent
- FDA's Foot-Dragging On Menthol Ban Sparks Frustration
- FDA Denies Marketing For 65 MNGO Disposable E-Cigarettes
- FDA Tells Justices It Has A Better Vape Case In Mind
- SEC Has Careful Eye On Disclosures Amid Israel-Hamas War
- 'Ringleader' Of Black Market HIV Drug Scam Gets 9 Years
- Patent Lessons From 8 Federal Circuit Reversals In March
- Manatt Adds NY Bankruptcy, Financial Regulatory Partners
- WashU Medical School Settles Claims Of Asylee Bias, Firing
- Ex-Pharma Exec's Contempt Plea Rejected By Judge
- Elliott Waives BioMarin Board Deal, Moots Del. Suit
- A Look At Ex Parte Seizures 8 Years Post-DTSA
- Whitewater Kayaking Makes Me A Better Lawyer
- House Panel Takes Aim At Change Healthcare, FTC Over Hack
- Eli Lilly's Insulin Price Cap Deal Collapses After Cert. Denial
- NC Treasurer Backs FTC On Hospital Merger Challenge
- IBM Gained Most AI Patents By Far In 2023
- AI In The Operating Room: Liability Issues For Device Makers
- Del. Lessons For Director-Nominees On Sharing With Activists
- Life Sciences Group Of The Year: Fenwick
- 10 Years After Alice, Predictability Debate Lingers
- This Earth Day, Consider How Your Firm Can Go Greener
- Taro Inks $36M Investor Deal Over Generics Price-Fixing
- Chancery Denies Forte Biosciences' Bid To Toss Investor Suit
- Years After Args, 7th Circ. Continues Mootness Fee Attack
- TTAB Sides With Pharma Co.'s Opposition To 'SageForth' TM
- Hold This COVID Vax Patent Case, Judge Recommends
- Catching Up With Delaware's Chancery Court
- Orrick Adds Kramer Levin Life Sciences Head In NY
- Pharmacy, Courier Co. Settle Driver's Classification Suit
- Justices Won't Nix FDA Labeling Preemption For State Claims
- Life Sciences Group Of The Year: Cooley
- Moderna, Pfizer COVID Vax IP Suit Paused Amid PTAB Review
- Ex-Biotech CEO Gets 7 Years In Fake COVID Test Case
- DEA Unlawfully Pushing Psychedelics Ban, Researcher Says
- Abbott Labs Gets Price Claims Tossed In Baby Formula MDL
- Questions Persist After Ruling Skirts $925M TCPA Award Issue
- Benzene Contamination Concerns: Drugmakers' Next Steps
- Ex-Pfizer Worker's Pal Avoids Prison In Insider Trading Case
- Trade Groups Urge Senators To Advance Patent Reform Bills
- States Should Follow Federal Lead On Expert Evidence Rules
- Woman Pleads Guilty To $1.3M COVID Tax Credit Fraud
- Life Sciences Group Of The Year: Latham
- US-based MSD Broke Ban On Using 'Merck' In UK, Court Finds
- Zoll Says 'Cookie-Cutter' Hack Claims Don't Show Harm
- EU Approves Biotech Co. Illumina's Plan To Divest Grail
- Asbury Park Escapes Pot Co.'s Zoning Board Conspiracy Suit
- Sandoz Says Feds Misclassified Generics As 'Innovator Drugs'
- Fed. Circ. Blocks Alvogen Generic Of Bausch Diarrhea Drug
- FDA Commissioner Says Congress Must Act On Hemp, CBD
- 9th Circ. Nixes 'Super Snap Removals' In Dexcom Suits
- Birth Control Injury Claims Barred From Conn., Court Told
- Deals Rumor Mill: US Steel, Germany's Stada, Paramount
- Del. Justices OK Denial Of Icahn-Illumina Midcase Appeal Bid
- Medtronic Can't Ditch Ex-Sales Rep's Retaliation Claim
- The Pros And Cons Of NIST's Proposed March-In Framework
- Kirkland, Jones Day Build $787.5M Sale Of Steris' Dental Unit
- Life Sciences Group Of The Year: Sullivan & Cromwell
- Pfizer Unit Cuts $39M Deal Ending Effexor Antitrust Claims
- DOJ Hits Regeneron With False Claims Act Suit Over Eylea
- Del. Justices Probe Validity Of Advance Notice Bylaws
- 9th Circ. Mostly Affirms Industry Ban For COVID PPE Delays
- Dems Introduce Bill To Codify Policy Barring Judge Shopping
- 4th Circ. Sides With CMS' Definition Of 'Line-Extension Drug'
- Skadden, Fenwick Lead $4.9B Alpine Immune Sciences Sale
- Pharmacy Gets Eli Lilly's Mounjaro Suit Tossed
- Justices Asked To Ban FCA Suits Relying On Patent Reviews
- Moderna Says Pfizer Is PTAB 'Tea-Leaf-Reading' In Vax IP Row
- Federal MDL Rule Benefits From Public Comments
- 1st Circ. Says Appellant's Death Erases Conviction
- Practicing Law With Parkinson's Disease
- Life Sciences Group Of The Year: Morrison Foerster
- Ginkgo Bioworks SPAC Investors Sue In Del. After Stock Drop
- After Uproar, New MDL Rule Advances With Attys Assuaged
- Investor Can't Get Approval Of Hong Kong Award In Calif.
- Philips, Feds Enter Consent Decree Over Sleep Apnea Devices
- Pfizer Cancer Drug Way Too Expensive, Biden Told
- HK Arbitrator Halts Commercialization Of Leukemia Treatment
- Former Pharma Exec Can't Oust Judge In Contempt Case
- Endo Sues FDA Over Generic Adrenalin Approvals
- Biotech Co. Insiders Sued In Del. Over $200M PIPE Deal Gain
- Tech M&A Reigns Supreme In Q1 After Rare Hiccup In Q4
- When Trade Secret Protection And Nat'l Security Converge
- The Merger Cases That Will Matter At ABA Antitrust Meeting
- Life Sciences GCs On Tighter Regs, Outside Counsel Advice
- Calif. Verdict Showcases SEC's New 'Shadow Trading' Theory
- Jenner & Block Recruits Ex-Sheppard Mullin IP Litigator In SF
- Court OKs Decision Clearing Contractor Of Missed IP Deadline
- Playing Hockey Makes Me A Better Lawyer
- Target's Acne Treatments Contain Benzene, Customer Says
- Walmart Beats Investor Suit Over Opioid Probe Disclosures
- SEC 'Shadow Trading' Victory Could Bring DOJ Knocking
- Roche Again Beats Ex-Service Members' Antimalarial Drug Suit
- 9th Circ. Urged To Revive J&J, Bausch Talc False Ad Suit
- La. Drug Caps Conflict With Federal Law, AbbVie Says
- PE Firm Calls FTC's Antitrust Claims 'Many Yesterdays' Old
- Catching Up With Delaware's Chancery Court
- FDA Finds No Asbestos In Cosmetic Talc Products
- For Lawyers, Pessimism Should Be A Job Skill, Not A Life Skill
- Goodwin Adds 5-Atty Tech Team From Cooley In Boston
- Kirkland-Led Vista Buying Medtech Co. 'Model N' For $1.25B
- Apple Asks Fed. Circ. To Upend ITC Watch Feature Ban
- 'Take The Win,' Judge Tells Texas In HHS Abortion Pill Suit
- Abbott Settles TM Suit Over Gray Market Diabetes Test Strips
- Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
- Fed. Circ. Says Sumitomo's Expired Drug Patent Moots Appeal
- Texas Man Gets 7 Years For COVID Testing Fraud
- Ex-Biopharma Officer Seeks Defense Fees Over Fraud Suit
- Mich. Plaintiffs Bar Prepares For Growth After Policy Shifts
- Publix Wants Ga. High Court Input On Opioid Public Nuisance
- Jury Finds Pharma Exec 'Shadow Traded' With Inside Info
- HHS Opioid Rule Generally Benefits Providers And Patients
- New Chancery Challenge Launched To Board-Investor Pacts
- Mo. High Court Affirms Co.'s Medical Pot License Denial
- Gunderson, Sidley Steer Biotech's Scaled-Down $110M IPO
- Trump's NY Civil Fraud Trial Spotlights Long-Criticized Law
- UK Litigation Roundup: Here's What You Missed In London
- Freshfields Reps J&J On $13.1B Deal For Shockwave Medical
- SEC Points Jury To 'Coincidence' In Shadow Trading Trial
- Tribes And McKinsey Take Final Step In $39.5M Opioid Deal
- NY AG Asked To Weigh In On Multiple Sclerosis Drug Fight
- Latham Led Firms In 1st Quarter IPOs As Outlook Brightens
- Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents
- Novo Holdings, Catalent Reset Review Clock On $16.5B Deal
- Structure Defense Remains In FTC Hospital Case, But Not Hearing
- Nurses Want To Merge DaVita Wage Suits Over Unpaid Breaks
- Higher Ed Groups Warn Of 'Radical Shift' In Suicide Liability
- UK Billionaire Lewis Avoids Prison For Insider Trading
- Squire Patton Adds Polsinelli Enviro Atty Pair In Denver
- Requiring Leave To File Amicus Briefs Is A Bad Idea
- Boston Scientific's $3.7B Axonics Buy Under FTC Microscope
- 2 Recent Suits Show Resiliency Of Medicare Drug Price Law
- Kirkland-Led SK Capital Raises $2.95B For 6th PE Fund
- Sanofi Plans To Settle 4,000 Zantac Cancer Claims
- Accused 'Shadow Trader' Takes Stand To Slam SEC's Case
- Microsoft Notches Fed. Circ. Win In 3D Imaging Patent Fight
- UK Billionaire Lewis Agrees To $1.64M Insider Trading Penalty
- Philly Injection Site Org. Isn't Religious, Judge Rules
- Sen. Durbin Urged To Pass Legislation To Curb Judge Shopping
- 4 Ways To Motivate Junior Attorneys To Bring Their Best
- Genmab Builds Oncology Portfolio With $1.8B Deal
- McDermott Adds Ex-Baker McKenzie Tax Pro In Chicago
- Hospital Workers' Vax Free Speech Suit Falls Flat At 6th Circ.
- Pharma Exec, Cousin Cop To Insider Trading On Kodak Loan
- Defense Attys Must Prep For Imminent AI Crime Enforcement
- Alaska Judge Tosses Opioid Nuisance Case Against Pharmacies
- 9th Circ. To Hear Ex-Theranos Execs' Criminal Appeals In June
- Lupin Scores Win In Rosacea Patent Fight With Galderma
- Theseus Investor Seeks Appraisal After Concentra Merger
- Teva Has Remedy For Generic EpiPen Takings, Colo. Says
- Fed. Circ. Seems Ready To Revive Amarin's Skinny Label Suit
- Mich. Warns PFAS Ruling Could Fuel More Agency Challenges
- NM Medical Cannabis Insurance Row To Stay In Federal Court
- Daiichi Gets Award Nixing Seagen Cancer Drug Claims OK'd
- Planning For Healthcare-Private Equity Antitrust Enforcement
- Why USPTO Should Issue Inherency Guidance Memo
- McCarter & English's Client Contract Win Heads To Mediation
- How Purdue Pharma High Court Case May Change Bankruptcy
- Feds Seek Leniency For UK Billionaire Lewis In Trading Case
- 3 Health Insurance Paths For Psychedelic-Assisted Therapy
- Serving As A Sheriff's Deputy Made Me A Better Lawyer
- Acorda Therapeutics Hits Ch. 11, Plans $185M Drug Sale
- Inotiv Can't Toss Investor Suit Over Feds' 'Puppy Mill' Probe
- Pharma Co. Beats Investor Suit Over Wrinkle Drug Approval
- Apple, Intel Again Lose Fintiv APA Challenge In Calif. Court
- Optical Co. Beats Investor Suit Over Pandemic Staffing Levels
- 'Unreliable' Theory Dooms City's Acthar Antitrust Cert. Bid
- Fed. Circ. Revives Challenges To J&J Schizophrenia Drug
- Catching Up With Delaware's Chancery Court
- Fears About The End Of Chevron Deference Are Overblown
- Ex-Pharma Co. Exec Denies Signing Noncompete Deal
- J&J Opted To 'Deny' Talc-Cancer Link, Jury Told
- Gunderson-Led Contineum Joins Pipeline Eyeing $150M IPO
- Fla. High Court Says Voters Will Choose Whether To Legalize Pot
- Negotiating Milestones In Pharma Licenses Requires Care
- Masimo Rips Politan's New Attempt To Grab Board Seats
- Eiger BioPharmaceuticals Hits Ch. 11 With $53.1M Debt
- Former Minn. Chief Justice Instructs On Writing Better Briefs